Effect of aspirin on mortality in women with symptomatic or silent myocardial ischemia

American Journal of Cardiology

Volumn 78, Issue 11, 1996, Pages 1215-1219

  Harpaz, David ^a   Benderly, Michal ^b   Goldbourt, Uri ^b   Kishon, Yehezkiel ^b   Behar, Solomon ^b  

^a WOLFSON MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIGITALIS GLYCOSIDE;

AGED; ARTICLE; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HUMAN; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVAL RATE;

AGED; ASPIRIN; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; CORONARY DISEASE; DIGITALIS GLYCOSIDES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL RATE;

EID: 0030331845     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00598-X     Document Type: Article

References (11)

1. Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Kaplinsky E, Graff E, Kishon Y, Caspi A, Waysbort J, Mandelzweig L, Abinader E, Aharon L, et al, for the Bezafibrate Infarction Prevention Study Group. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardial 1993;71:909-915.
2. SAS Institute Inc., SAS® Procedures Guide, version 6, 3rd ed. Cary, NC: SAS Institute Inc., 1990;325-364.
3. SAS Institute Inc., SAS Technical report P-229, SAS/STAT software: Changes and enhancements release 6.07, Cary, NC: SAS Institute Inc., 1992;433-480.
4. Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980; 243:661-669.
5. Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. Lancet 1979;22/29:1313-1315.
6. Antiplatelet Trialist's Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106.
7. Escolar G, Bastida E, Garrido M, Rodriguez-Gomez J, Castillo R, Ordinas A. Sex-related differences in the effects of aspirin of the interaction of platelets with subendothelium. Thromb Res 1986;44:837-847.
8. Spranger M, Aspey BS, Harrison MJC. Sex difference in antithrombotic effect of aspirin. Stroke 1989;20:34-37.
9. Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978;299:53-59.
10. Husted SE, Pedersen AK, Petersen T, Geday E. Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. Eur J Clin Pharmacol 1983;24:679-682.
11. Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 1989;80:749-756.